| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.VACCINE.2009.10.111 |
| P698 | PubMed publication ID | 19896452 |
| P2093 | author name string | Drew Hannaman | |
| Stephen F Little | |||
| Alain Luxembourg | |||
| Barry Ellefsen | |||
| Brian D Livingston | |||
| P2860 | cites work | DNA vaccines: immunology, application, and optimization* | Q28145651 |
| Protective antigen as a correlative marker for anthrax in animal models | Q28391302 | ||
| Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial | Q28972526 | ||
| A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses | Q30228657 | ||
| Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax | Q30859738 | ||
| Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine | Q33195848 | ||
| Recombinant protective antigen 102 (rPA102): profile of a second-generation anthrax vaccine | Q33258307 | ||
| PLGA-dendron nanoparticles enhance immunogenicity but not lethal antibody production of a DNA vaccine against anthrax in mice | Q33270601 | ||
| Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults | Q33299673 | ||
| Protective antigen-mediated antibody response against a heterologous protein produced in vivo by Bacillus anthracis | Q33592070 | ||
| Search for correlates of protective immunity conferred by anthrax vaccine | Q34007168 | ||
| Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adults | Q34582387 | ||
| Induction of immune responses by DNA vaccines in large animals | Q35046978 | ||
| Technical and regulatory hurdles for DNA vaccines | Q35143252 | ||
| Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults | Q35667935 | ||
| Cytotoxic T-lymphocyte-, and helper T-lymphocyte-oriented DNA vaccination | Q35682500 | ||
| Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques | Q35857581 | ||
| Plasmid DNA vaccines against cancer: cytotoxic T-lymphocyte induction against tumor antigens | Q36198661 | ||
| Anthrax vaccines: a development update | Q36243294 | ||
| Rational design of gene-based vaccines | Q36346123 | ||
| Markedly enhanced immunogenicity of a Pfs25 DNA-based malaria transmission-blocking vaccine by in vivo electroporation | Q36428352 | ||
| Past, imminent and future human medical countermeasures for anthrax | Q36565152 | ||
| Preclinical and clinical safety studies on DNA vaccines | Q36609096 | ||
| Clinical phase 1 testing of the safety and immunogenicity of an epitope-based DNA vaccine in human immunodeficiency virus type 1-infected subjects receiving highly active antiretroviral therapy | Q36746882 | ||
| Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells | Q36780146 | ||
| Electroporation-based DNA immunisation: translation to the clinic | Q36981658 | ||
| Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies | Q37033046 | ||
| Vaccines: countering anthrax: vaccines and immunoglobulins | Q37048682 | ||
| Current progress of DNA vaccine studies in humans | Q37103923 | ||
| Frequency and domain specificity of toxin-neutralizing paratopes in the human antibody response to anthrax vaccine adsorbed | Q37191250 | ||
| A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A. | Q37258250 | ||
| DNA vaccination and gene therapy: optimization and delivery for cancer therapy | Q37259636 | ||
| DNA vaccines: developing new strategies to enhance immune responses | Q37344615 | ||
| Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis | Q37404847 | ||
| A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores | Q37533817 | ||
| Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization | Q40008502 | ||
| Neutralizing activity of vaccine-induced antibodies to two Bacillus anthracis toxin components, lethal factor and edema factor | Q40046283 | ||
| DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial | Q40392276 | ||
| Protection against plague afforded by immunisation with DNA vaccines optimised for expression of the Yersinia pestis V antigen | Q41462618 | ||
| In vitro correlate of immunity in a rabbit model of inhalational anthrax | Q43727746 | ||
| Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation | Q44084317 | ||
| Enhancement of immune responses to an HBV DNA vaccine by electroporation | Q44643829 | ||
| Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults | Q45398885 | ||
| Potentiation of an anthrax DNA vaccine with electroporation | Q46607685 | ||
| Of mice and men: species variations of Toll-like receptor expression | Q74499741 | ||
| Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques | Q74818408 | ||
| Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial | Q79782971 | ||
| Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation | Q81255648 | ||
| Electroporation-based DNA transfer enhances gene expression and immune responses to DNA vaccines in cattle | Q81792807 | ||
| DNA vaccines | Q93896322 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vaccine | Q134808 |
| electroporation | Q1142521 | ||
| P304 | page(s) | 1056-1061 | |
| P577 | publication date | 2009-11-05 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Comparative performance of a licensed anthrax vaccine versus electroporation based delivery of a PA encoding DNA vaccine in rhesus macaques | |
| P478 | volume | 28 |
| Q35853440 | A CpG-Ficoll Nanoparticle Adjuvant for Anthrax Protective Antigen Enhances Immunogenicity and Provides Single-Immunization Protection against Inhaled Anthrax in Monkeys. |
| Q35066196 | A DNA vaccine for venezuelan equine encephalitis virus delivered by intramuscular electroporation elicits high levels of neutralizing antibodies in multiple animal models and provides protective immunity to mice and nonhuman primates |
| Q37999969 | A brief overview of electroporation pulse strength-duration space: a region where additional intracellular effects are expected |
| Q36378590 | A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques |
| Q45874005 | Adipose tissue: a new target for electroporation-enhanced DNA vaccines |
| Q44140969 | Assessment of delivery parameters with the multi-electrode array for development of a DNA vaccine against Bacillus anthracis. |
| Q41755913 | Comprehensive analysis and selection of anthrax vaccine adsorbed immune correlates of protection in rhesus macaques |
| Q33589738 | Control of HPV-associated tumors by innovative therapeutic HPV DNA vaccine in the absence of CD4+ T cells |
| Q39690078 | DNA vaccine expressing HIV-1 gp120/immunoglobulin fusion protein enhances cellular immunity |
| Q41909657 | Delivery of a DNA vaccine for Alzheimer's disease by electroporation versus gene gun generates potent and similar immune responses |
| Q34241550 | Development of a highly efficacious vaccinia-based dual vaccine against smallpox and anthrax, two important bioterror entities |
| Q42246468 | Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: a randomized trial |
| Q37870313 | Electroporation delivery of DNA vaccines: prospects for success |
| Q42998889 | Electroporation enhances immune responses and protection induced by a bovine viral diarrhea virus DNA vaccine in newborn calves with maternal antibodies |
| Q37744992 | Electroporation for DNA immunization: clinical application |
| Q41414313 | Electroporation of a multivalent DNA vaccine cocktail elicits a protective immune response against anthrax and plague |
| Q91797383 | Electroporation-Mediated Immunization of a Candidate DNA Vaccine Expressing Dengue Virus Serotype 4 prM-E Antigen Confers Long-Term Protection in Mice |
| Q35796747 | Enhanced Immune Response to DNA Vaccine Encoding Bacillus anthracis PA-D4 Protects Mice against Anthrax Spore Challenge |
| Q46007395 | Enhanced magnitude and breadth of neutralizing humoral response to a DNA vaccine targeting the DHBV envelope protein delivered by in vivo electroporation. |
| Q34307955 | Highly effective generic adjuvant systems for orphan or poverty-related vaccines |
| Q45372954 | Immunogenicity and protective efficacy of a DNA vaccine against Venezuelan equine encephalitis virus aerosol challenge in nonhuman primates |
| Q28728563 | Immunogenicity of DNA vaccines encoding simian immunodeficiency virus antigen targeted to dendritic cells in rhesus macaques |
| Q91882087 | Immunogenicity of a protective intradermal DNA vaccine against lassa virus in cynomolgus macaques |
| Q45031334 | Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in vivo electroporation |
| Q28744555 | In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers |
| Q36297880 | In vivo molecular imaging and histological analysis of changes induced by electric pulses used for plasmid DNA electrotransfer to the skin: a study in a dorsal window chamber in mice. |
| Q37713895 | Novel vaccine regimen elicits strong airway immune responses and control of respiratory syncytial virus in nonhuman primates |
| Q40053603 | Nucleic acid-based vaccines targeting respiratory syncytial virus: delivering the goods |
| Q34964980 | Protective efficacy and immunogenicity of a combinatory DNA vaccine against Influenza A Virus and the Respiratory Syncytial Virus |
| Q37530303 | Protective-antigen (PA) based anthrax vaccines confer protection against inhalation anthrax by precluding the establishment of a systemic infection |
| Q38176047 | Skin permeabilization for transdermal drug delivery: recent advances and future prospects |
| Q37276912 | Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants. |
| Q35802958 | Technologies for enhanced efficacy of DNA vaccines |
| Q43061847 | The Electrode Modality Development in Pulsed Electric Field Treatment Facilitates Biocellular Mechanism Study and Improves Cancer Ablation Efficacy. |
| Q38583019 | Transdermal drug delivery: feasibility for treatment of superficial bone stress fractures. |
Search more.